GORT

Reviews

Fda Approves First Immunotherapy Treatment For Lung Cancer

Di: Everly

“ We are thrilled about the FDA’s expanded use of the cancer immunotherapy drug, nivolumab, as the first and only immunotherapy-based treatment for use before surgery

Frontiers | Immunotherapy in non-small cell lung cancer: Past, present ...

Non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease.

Harnessing local and system immune profiling delineating

On Friday, August 17, the FDA approved the first immunotherapy—the checkpoint inhibitor nivolumab (Opdivo®, Bristol-Myers Squibb)—for patients with small cell lung cancer

Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung

  • FDA approves first biosimilar for cancer treatment
  • FDA approves Libtayo® monotherapy for
  • FDA Approves Expanded Use of Nivolumab for Lung Cancer
  • Sotorasib is First KRAS Inhibitor Approved by FDA

In March of this year, the immunotherapy drug nivolumab (Opdivo®), made by Bristol-Myers Squibb, became the first immunotherapy approved by the FDA for the treatment

5 December 2024 — AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease

On October 15, 2021, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment following resection and platinum-based chemotherapy in patients with

The FDA has approved nivolumab to treat patients with advanced non-small cell lung cancer that has progressed during or after treatment with platinum-based chemotherapy.

This week marked a significant milestone in the fight against cancer. On June 17, the FDA approved the cancer immunotherapy drug, pembrolizumab (Keytruda®), combined

On August 15, 2024, the FDA approved durvalumab (Imfinzi, AstraZeneca) with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as

[This article was originally published on August 29.] On August 29, the Food and Drug Administration (FDA) approved Rybrevant (amivantamab) plus Lazcluze (lazertinib) as a

  • Adjuvant Immunotherapy Approved for Lung Cancer
  • Harnessing local and system immune profiling delineating
  • Two New FDA Approvals in Lung Cancer
  • US FDA approves Amgen drug for small cell lung cancer

Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small cell lung cancer—which the company

Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a

Non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease.

Keytruda (pembrolizumab) received FDA approval as a first-line treatment for lung cancers that are inoperable, enhancing immunotherapy options. Eligibility for Keytruda treatment requires the absence of ALK or

FDA approves first immunotherapy regimen for breast cancer | CNN

Atezolizumab and pembrolizumab are both U.S. Food and Drug Administration (FDA) approved in the adjuvant settings for treatment of non–small cell lung cancer (NSCLC)

The U.S. Food and Drug Administration (FDA) has approved durvalumab (Imfinzi) for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) that did not progress after platinum-based chemotherapy and radiation. This is

AstraZeneca’s IMFINZI ® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease

The development of cancer immunotherapies, harnessing the immune system to restore anti-tumor immunity, has transformed the treatment of certain cancers. The first immune checkpoint

“The approval of Libtayo to treat first-line advanced non-small cell lung cancer with high PD-L1 expression means physicians and patients have a potent new treatment option

Approved 3 months ahead of schedule, nivolumab is the first immunotherapy to have shown a survival benefit in non-small cell lung cancer.

In March of this year, the immunotherapy drug nivolumab (Opdivo®), made by Bristol-Myers Squibb, became the first immunotherapy approved by the FDA for the treatment

Imfinzi recommended for approval in the EU by CHMP as first and only perioperative immunotherapy for muscle-invasive bladder cancer. News Release.

FDA approves atezolizumab as adjuvant treatment for non-small cell lung cancer. Published January 23, 2023. Accessed April 1, 2024. U.S. Food and Drug Administration. FDA approves pembrolizumab as adjuvant treatment

FDA has approved the first KRAS-blocking drug, called sotorasib (Lumakras). The approval, which covers the use of sotorasib for some patients with advanced lung cancer, was

While chemo-immunotherapy has been established as the frontline therapeutic regimen for extensive-stage small cell lung cancer (ES-SCLC), durable responses persist

FDA has approved the immunotherapy atezolizumab (Tecentriq) as an additional, or adjuvant, treatment for some patients with non-small cell lung cancer (NSCLC). With the

The FDA approved the first immunotherapy treatment for lung cancer in 2015. Tecentriq is only one of many immunotherapies studied in recent clinical trials involving

The Food and Drug Administration (FDA) has approved Emrelis ™ (telisotuzumab vedotin-tllv) for the treatment of adult patients with locally advanced or metastatic non

Imfinzi was first approved by the FDA in 2017 for use against various lung and liver cancers, either alone or along with other treatments. Imfinzi is now the first and only